WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer reports first-quarter 2014 results 06 May 2014
Pfizer sends letter to Rt Hon David Cameron MP regarding commitments if proposed combination with AstraZeneca is completed 01 May 2014
Pfizer Confirms prior discussions with AstraZeneca 28 April 2014
Eliquis® (apixaban) reduced the risk of stroke and demonstrated fewer major bleeding events versus Warfarin 23 February 2014
Pfizer and Merck to collaborate on innovative anti-cancer combination studies 06 February 2014
Pfizer reports fourth-quarter and full-year 2013 results 29 January 2014
Pfizer settles Viagra® patent litigation with Teva 17 December 2013
Pfizer expands clinical trial data access policy and launches data access portal 09 December 2013
Pfizer acquires Polocard, Poland's leading over-the-counter heart attack prevention brand 03 December 2013
Pfizer and GSK to initiate study of novel combination therapy in patients with melanoma 21 November 2013
Pfizer reports third quarter 2013 results 30 October 2013
International Atherosclerosis Society and Pfizer Independent Grants for Learning & Change collaborate on new grant opportunity 03 October 2013
Pfizer to create separate, internal, global Innovative and Value businesses 30 July 2013
Pfizer statement on PhRMA-EFPIA principles for responsible clinical trial data sharing 25 July 2013
Pfizer obtains $2.15 billion settlement from Teva and Sun for infringement of Protonix® patent 12 June 2013
United States Patent & Trademark Office grants Pfizer reissue patent for Celebrex® 05 March 2013
Pfizer and AstraZeneca enter into agreement for over-the-counter Nexium 13 August 2012
Pfizer reports second-quarter 2012 results 31 July 2012
Pfizer reports top-line results of study of Lyrica's effect on male reproduction 23 July 2012
Pfizer provides topline results from Phase 3 study of Torisel® 16 May 2012
  • Start
  • Prev
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • Next
  • End
Build the future of health through collaboration & innovation

Business & Industry

  • Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
  • AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX
  • Abbott researchers find rare group of people with controlled HIV who could be a key to unlocking cure
  • Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants
  • Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate

Research & Development

  • New evidence COVID-19 antibodies, vaccines less effective against variants
  • Vaccine development software shows promise in influenza effort, could help defeat coronavirus
  • Researchers discover SARS-CoV-2 inhibitors
  • Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studies
  • First COVID-19 COVAX vaccine doses administered in Africa
  • Assessing a compound's activity, not just its structure, could accelerate drug discovery
  • Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients

Conferences & Events

  • Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production

Regulatory Affairs

  • FDA issues Emergency Use Authorization for third COVID-19 vaccine
  • FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.